A thermally stable form of bacterial cocaine esterase: A potential therapeutic agent for treatment of cocaine abuse

Molecular Pharmacology

Volumn 77, Issue 4, 2010, Pages 593-600

  Brim, Remy L ^a   Nance, Mark R ^b   Youngstrom, Daniel W ^b   Narasimhan, Diwahar ^a   Zhan, Chang Guo ^c   Tesmer, John J G ^a,b   Sunahara, Roger K ^a   Woods, James H ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLESTERASE; COCAINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CRYSTAL STRUCTURE; DISEASE MODEL; DRUG ABUSE; DRUG DEPENDENCE; DRUG HALF LIFE; ENZYME ANALYSIS; ENZYME STABILITY; HYDROGEN BOND; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; THERMOSTABILITY;

ANIMALS; CARBOXYLIC ESTER HYDROLASES; COCAINE-RELATED DISORDERS; CRYSTALLOGRAPHY; ENZYME STABILITY; HALF-LIFE; MALE; MICE; RATS; RATS, SPRAGUE-DAWLEY; REINFORCEMENT (PSYCHOLOGY); RHODOCOCCUS; TEMPERATURE;

EID: 77950212804     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.060806     Document Type: Article

References (39)

1. Benowitz NL (1993) Clinical pharmacology and toxicology of cocaine. Pharmacol Toxicol 72:3-12.
2. Billman GE (1990) Mechanisms responsible for the cardiotoxic effects of cocaine. FASEB J 4:2469-2475.
3. Bresler MM, Rosser SJ, Basran A, and Bruce NC (2000) Gene cloning and nucleotide sequencing and properties of a cocaine esterase from Rhodococcus sp. strain MB1. Appl Environ Microbiol 66:904-908.
4. Brimijoin S, Gao Y, Anker JJ, Gliddon LA, Lafleur D, Shah R, Zhao Q, Singh M, and Carroll ME (2008) A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. Neuropsychopharmacology 33:2715-2725.
5. Browne SP, Slaughter EA, Couch RA, Rudnic EM, and McLean AM (1998) The influence of plasma butyrylcholinesterase concentration on the in vitro hydrolysis of cocaine in human plasma. Biopharm Drug Dispos 19:309-314.
6. Carroll FI, Howard JL, Howell LL, Fox BS, and Kuhar MJ. AAPS J 8:E196-E203.
7. Collaborative Computational Project Number 4 (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50:760-763.
8. Collins GT, Brim RL, D. Narasimhan D, Ko MC, Sunahara RK, Zhan CG, and Woods JH (2009) Cocaine esterase prevents cocaine-induced toxicity and the ongoing intravenous self-administration of cocaine in rats. J Pharmacol Exp Ther 331:445-455.
9. Cooper ZD, D. Narasimhan D, Sunahara RK, Mierzejewski P, Jutkiewicz EM, Larsen NA, Wilson IA, Landry DW, and Woods JH (2006) Rapid and robust protection against cocaine-induced lethality in rats by the bacterial cocaine esterase. Mol Pharmacol 70:1885-1891.
10. Couper FJ and Logan BK (2004) Drug and Human Performance Fact Sheets, Report No. DOT HS 809 725, National Highway Traffic Safety Administration, Washington DC. Available at http://www.nhtsa.gov/PEOPLE/INJURY/research/ job185drugs/drugs-web.pdf.
11. Crumb WJ, Jr. and Clarkson CW (1990) Characterization of cocaine-induced block of cardiac sodium channels. Biophys J 57:589-599.
12. Daniels A, Ayala E, Chen W, Coop A, and Matsumoto RR (2006) N-[2-(mmethoxyphenyl) ethyl]-N-ethyl-2-(1-pyrrolidinyl)ethylamine (UMB 116) is a novel antagonist for cocaine-induced effects. Eur J Pharmacol 542:61-68.
13. Duysen EG, Bartels CF, and Lockridge O (2002) Wild-type and A328W mutant human butyrylcholinesterase tetramers expressed in Chinese hamster ovary cells have a 16-hour half-life in the circulation and protect mice from cocaine toxicity. J Pharmacol Exp Ther 302:751-758.
14. Edwards JA and Brimijoin S (1983) Thermal inactivation of the molecular forms of acetylcholinesterase and butyrylcholinesterase. Biochimica et Biophysica Acta 742:509-516.
15. Emsley P and Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126-2132.
16. Gao D, D. Narasimhan DL, Macdonald J, Brim R, Ko MC, Landry DW, Woods JH, Sunahara RK, and Zhan CG (2009) Thermostable variants of cocaine esterase for long-time protection against cocaine toxicity. Mol Pharmacol 75:318-323.
17. Gao Y and Brimijoin S (2004) An engineered cocaine hydrolase blunts and reverses cardiovascular responses to cocaine in rats. J Pharmacol Exp Ther. 310:1046-1052.
18. Gao Y, LaFleur D, Shah R, Zhao Q, Singh M, and Brimijoin S (2008) An albumin-butyrylcholinesterase for cocaine toxicity and addiction: catalytic and pharmacokinetic properties. Chem Biol Interact 175:83-87.
19. Gorelick DA (1997) Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy. Drug Alcohol Depend 48:159-165.
20. Hoffman RS, Morasco R, and Goldfrank LR (1996) Administration of purified human plasma cholinesterase protects against cocaine toxicity in mice. J Toxicol Clin Toxicol 34:259-266.
21. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
22. Johanson CE and Fischman MW (1989) The pharmacology of cocaine related to its abuse. Pharmacol Rev 41:3-52.
23. Jutkiewicz EM, Baladi MG, Cooper ZD, D. Narasimhan D, Sunahara RK, and Woods JH (2009) A Bacterial Cocaine Esterase Protects Against Cocaine-Induced Epileptogenic Activity and Lethality. Ann Emerg Med 54:409-420.
24. Ko MC, Bowen LD, D. Narasimhan D, Berlin AA, Lukacs NW, Sunahara RK, Cooper ZD, and Woods JH (2007) Cocaine esterase: interactions with cocaine and immune responses in mice. J Pharmacol Exp Ther 320:926-933.
25. Larsen NA, Turner JM, Stevens J, Rosser SJ, Basran A, Lerner RA, Bruce NC, and Wilson IA (2002) Crystal structure of a bacterial cocaine esterase. Nat Struct Biol 9:17-21.
26. Lovell SC, Davis IW, Arendall III WB, de Bakker PIW, Word JM, Prisant MG, Richardson JS, and Richardson DC (2003) Structure validation by C-alpha geometry: phi, psi, and C-beta deviation. Protein Struct Funct Genet 50:437-450.
27. Lynch TJ, Mattes CE, Singh A, Bradley RM, Brady RO, and Dretchen KL (1997) Cocaine detoxification by human plasma butyrylcholinesterase. Toxicol Appl Pharmacol 145:363-371.
28. Mattes CE, Lynch TJ, Singh A, Bradley RM, Kellaris PA, Brady RO, and Dretchen KL (1997) Therapeutic use of butyrylcholinesterase for cocaine intoxication. Toxicol Appl Pharmacol 145:372-380.
29. Negus SS, Mello NK, Kimmel HL, Howell LL, and Carroll FI (2009) Effects of the monoamine uptake inhibitors RTI-112 and RTI-113 on cocaine- and food-maintained responding in rhesus monkeys. Pharmacol Biochem Behav 91:333-338.
30. Office of National Drug Control Policy (2004) The Economic Costs of Drug Abuse in the United States, 1992-2002, Publication No. 207303, Executive Office of the President, Washington, DC. Available at http://www.ncjrs.gov/ondcppubs/ publications/pdf/economic-costs.pdf.
31. Otwinowski Z and Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276:307-326.
32. Pan Y, Gao D, Yang W, Cho H, Yang G, Tai HH, and Zhan CG (2005) Computational redesign of human butyrylcholinesterase for anticocaine medication. Proc Natl Acad Sci USA 102:16656-16661.
33. Rothman RB, Blough BE, and Baumann MH (2007) Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions. AAPS J 9:E1-10.
34. Substance Abuse and Mental Health Services Administration (2007) Results from the 2006 National Survey on Drug Use and Health: National Findings, Office of Applied Studies, NSDUH Series H-32, DHHS Publication no. SMA 07-4293, Rockville, MD.
35. Turner JM, Larsen NA, Basran A, Barbas CF 3rd, Bruce NC, Wilson IA, and Lerner RA (2002) Biochemical characterization and structural analysis of a highly proficient cocaine esterase. Biochemistry 41:12297-12307.
36. Uhl GR, Hall FS, and Sora I (2002) Cocaine, reward, movement and monoamine transporters. Mol Psychiatry 7:21-26.
37. Wood SK, D. Narasimhan D, Cooper Z, Sunahara RK, and Woods JH (2010) Prevention and reversal by cocaine esterase of cocaine-induced cardiovascular effects in rats. Drug Alcohol Depend 106:219-229
38. Xie W, Altamirano CV, Bartels CF, Speirs RJ, Cashman JR, and Lockridge O (1999) An improved cocaine hydrolase: the A328Y mutant of human butyrylcholinesterase is 4-fold more efficient. Mol Pharmacol 55:83-91.
39. Zheng F, Yang W, Ko MC, Liu J, Cho H, Gao D, Tong M, Tai HH, Woods JH, and Zhan CG (2008) Most efficient cocaine hydrolase designed by virtual screening of transition states. J Am Chem Soc 130:12148-12155.